Liraglutide (NN2211) is a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic GLP-1 that stimulates insu.lin secretion. 
Marketed under the brand name Victoza,Liraglutide is an injectable developed by Novo Nordisk for the treatment of type 2 diabetes. In 2015, Novo Nordisk began marketing Liraglutide in the U.S. and E.U. under the brand name Saxenda as a treatment for adults, who are obese or overweight with at least one weight-relatedcomorbid condition.

LIn common to various degrees with other GLP-1 receptor agonists,liraglutide has advantages over more traditional therapies for type 2 diabetes:
1. Liraglutide acts in a glucose-dependent manner, meaning Liraglutide will stimulate insu.lin secretion only when blood glucose levels are higher than normal, preventing "overshoot".Consequently, Liraglutide shows negligible risk of hypoglycemia.
2. Liraglutide has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies).
3. Liraglutide decreases appetite and inhibits body weight gain,as shown in a head-to-head study versus glimepiride.
4. Liraglutide lowers blood triglyceride levels.